No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ANVS Annovis Bio
- 18.010
- +4.410+32.43%
Close Apr 26 16:00 ET
- 17.440
- -0.570-3.16%
Post 19:52 ET
198.31MMarket Cap-2890P/E (TTM)
18.200High13.710Low1.06MVolume13.710Open13.600Pre Close17.32MTurnover13.01%Turnover RatioLossP/E (Static)11.01MShares22.49052wk High-25.58P/B146.65MFloat Cap5.42052wk Low--Dividend TTM8.14MShs Float132.000Historical High--Div YieldTTM33.02%Amplitude2.418Historical Low16.343Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up
Annovis Bio Is Maintained at Buy by HC Wainwright & Co.
Annovis Bio Is Maintained at Buy by HC Wainwright & Co.
Express News | HC Wainwright & Co. Maintains Buy on Annovis Bio, Maintains $30 Price Target
Annovis Bio GAAP EPS of -$6.23 Misses by $3.15
Buy Rating Reiterated for Annovis Bio Amid Anticipated Positive Trial Results for Alzheimer's and Parkinson's Treatments
Annovis Announces Publication That Supports Understanding Of Buntanetap's Mechanism Of Action In Humans
Further look at earlier Phase 1b study by ADCS unveils confirmatory dataMALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS), a clinical-stage drug platform company developin
Comments
$Annovis Bio(ANVS.US$ The effect of the drug in Alzheimer's is not significant, but its effect is better in Parkinson's disease. I think the Alzheimer's results that will be announced soon will be bad.
Hmm? VIA TIPRANKS JUST NOW!
$Annovis Bio(ANVS.US$ Annovis Bio Promises Market-Impacting Information Release. Hmm? Interesting? may be worth the potential loss? Just thinking outloud
2
Biotech Stock News 3/20
$Annovis Bio(ANVS.US$ 22% Ph2/3 data reporting update
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
10
1
$Annovis Bio(ANVS.US$ Annovis Bio Announced The Completion Of Data Cleaning For Its Phase 2/3 Study Of Buntanetap In Patients With Mild To Moderate Alzheimer's Disease. Topline Efficacy Data Is Expected In April
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg